Biotechnology
CDC will have less data to track Covid and new variants after public health emergency ends
People walk by a Covid-19 testing site at Times Square on May 12, 2022 in New York City. Liao Pan | China News Service | Getty Images The Centers for Disease Control and Prevention will have less data to track the spread of Covid-19 and new variants in the U.S. after the public health emergency […]
Read More
Kenvue CEO looks to brand, product innovation to drive growth after IPO
Thibaut Mongon, CEO of Kenvue Inc. a Johnson & Johnson consumer-health business, speaks during an interview with CNBC during his company’s IPO at the New York Stock Exchange (NYSE), May 4, 2023. Brendan McDermid | Reuters Kenvue CEO Thibaut Mongon is betting on brand and product innovation to drive growth at the newly spun-out company […]
Read More
WHO declares end to Covid global public health emergency
Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), speaks during a news conference in Geneva, Switzerland, December 20, 2021. Denis Balibouse | Reuters The spread of Covid-19 is no longer a global public health emergency, the World Health Organization declared on Friday. “For more than a year, the pandemic has been on a […]
Read More
J&J’s consumer health spinoff Kenvue opens at $25.53, a 16% jump, in public market debut
Thibaut Mongon, CEO and Paul Ruh CFO of Kenvue Inc. a Johnson & Johnson’s consumer-health business, pose together during the company’s IPO at the New York Stock Exchange (NYSE) in New York City, U.S., May 4, 2023. Brendan McDermid | Reuters Johnson & Johnson‘s consumer health spinoff Kenvue jumped 16% in its market debut on […]
Read More
Moderna posts surprise quarterly profit despite waning demand for Covid vaccines
Moderna’s sign is seen outside of their headquarters in Cambridge, MA on March 11, 2021. Boston Globe | Getty Images Moderna on Thursday blew past estimates for first-quarter earnings and revenue, posting a surprise quarterly profit, despite lower demand for Covid vaccines, its only marketable product. The biotech company generated first-quarter sales of $1.9 billion, […]
Read More
Novo Nordisk cuts some U.S. supply of Wegovy being overweight drug as demand soars
Danish pharmaceutical company Novo Nordisk said Thursday it was slicing the source of starter doses of its weight problems drug Wegovy in the U.S. as it struggles to preserve up with surging demand from customers. Main Economic Officer Karsten Munk Knudsen told CNBC that halving the provide of Wegovy starter doses was supposed to make certain present patients could […]
Read More
FDA commissioner praises Eli Lilly Alzheimer’s treatment results
FDA Commissioner Dr. Robert Califf speaks at an event celebrating hearing aids being available over the counter at a Walgreens in Washington, D.C., Oct. 19, 2022. Nathan Posner | Anadolu Agency | Getty Images Food and Drug Commissioner Dr. Robert Califf praised results Eli Lilly announced Wednesday that a clinical trial showed its Alzheimer’s treatment […]
Read More
FDA approves GSK’s RSV vaccine for older adults, world’s first shot against virus
A GSK lab in London. Oli Scarff | Getty Images The Food and Drug Administration on Wednesday approved an RSV vaccine produced by GlaxoSmithKline for use on adults ages 60 and older. The approval, the first ever globally by a regulatory body for an RSV vaccine, is a decisive victory for GSK in a race […]
Read More
J&J’s consumer health business Kenvue is going public this week. Here’s what to know
Johnson & Johnson products on a shelf in a store in New York. Lucas Jackson | Reuters Johnson & Johnson‘s consumer health business, Kenvue, is expected to go public this week in the largest U.S. IPO in more than a year. That business is chock full of household names familiar to investors and the larger […]
Read More
CVS beats on earnings and revenue but lowers profit outlook
A CVS location in New York, US, on Thursday, Feb. 9, 2023. Stephanie Keith | Bloomberg | Getty Images CVS Health on Thursday reported first-quarter results that beat earnings and revenue expectations, but the company lowered its full-year profit guidance due to costs related to recent acquisitions. Shares fell more than 1% in premarket trading […]
Read More